论文部分内容阅读
因为安全性和有效性数据尚不充分,伏立康唑的说明书不推荐其在2岁以下儿童中使用。但是既往有报道,临床上在出现危及生命的系统性真菌感染和耐药真菌感染时,给予0~2岁患儿伏立康唑对临床结局有较好的改善。伏立康唑血药浓度有较大的个体差异,联合用药、基因多态性和口服生物利用度均会导致不可预知的剂量效应关系。2岁以下患儿如权衡利弊后仍需使用时,为达到更好的疗效,可能需要更高的伏立康唑给药剂量,应在使用期间监测血药浓度,目前给药方案仍属于探讨阶段。
Because data on safety and efficacy are not yet sufficient, voriconazole’s instructions are not recommended for use in children under 2 years of age. However, it has been previously reported that voriconazole given to children aged 0 to 2 years has a clinically significant improvement in clinical outcomes in the presence of life-threatening systemic fungal infections and drug-resistant fungal infections. Voriconazole plasma concentration has a greater individual differences, combination therapy, genetic polymorphism and oral bioavailability can lead to unpredictable dose-response relationship. In children under 2 years of age should be weighed after weighing the pros and cons, in order to achieve better efficacy, may require higher doses of voriconazole dose, blood concentration should be monitored during use, the current dosing program is still part of the exploration phase.